Innova Captab Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/apyguxart6go32x1p8dnro6h.pdf

Key Takeaways


Jammu Facility Ramp-Up

Lohariwala: "As a company, it is our top priority that how fast we reach at a ₹100 crore level from Jammu."

API Pricing & Revenue Mechanics

Bhasin: "We should be able to reach to a final conclusion or a more concrete conclusion where our this year of Jammu revenue will lie and subject to the stabilization of API prices."

Business Reorganization

Lohariwala: "With Sharon now fully integrated within the Innova framework and keeping in mind our business modality, we believe that this new structure better reflects the way we operate today and how we create value across our portfolio."

Baddi-to-Jammu Product Transfer

Lohariwala: "But as we progress, our planning is that the Baddi Cephalosporin will be 100% move towards the export-oriented business. And the Jammu facility as we have the domestic GST benefit as well, so that will cater to the domestic business."

Branded Generics & Export Growth


Cost Structure & Margin Outlook

Bhasin: "In the long run, when we are anticipating that Jammu will stabilize, we are surely anticipating a certain upward movement on our margins, but we should be able to provide a more clear picture in our coming quarters."

Guidance & Commitments

CommitmentSpecificsTimeline
Jammu revenue target₹400 crores in FY26FY26, subject to API price stabilization
Jammu quarterly run-rateReach ₹100 crore quarterly revenue levelNo date; top priority
Jammu PAT breakevenPAT positiveHoped for by end of FY26
Baddi revenue normalizationReturn to usual run-rateAfter product transfers normalize (no date)
Full-year revenue guidanceRetain existing guidanceConditional on API price stabilization

Key Metrics

MetricQ1 FY26
Revenue₹351.5 cr, +19% YoY
CDMO revenue₹249.5 cr, +8% YoY; 71% of total revenue
Branded generics revenue₹101.2 cr, +59% YoY
EBITDA₹56.6 cr, +28% YoY
EBITDA margin16.1%, up from 15.1% in Q1 FY25
PAT₹31 cr, +5% YoY
PAT margin8.8%
Jammu plant revenue₹60 cr in Q1; annual target ₹400 cr at constant API pricing
Jammu plant operational breakeven₹60–65 cr quarterly revenue
Jammu plant PAT breakeven₹100 cr quarterly revenue
Jammu plant utilizationless than 5%
ICL standalone business growth~26.5% YoY
API price declineas high as 20% in certain cases
GST incentive available~₹75 cr fixed; requires ~₹600–620 cr sales at current 12% rate